FRIEDMAN PAUL A
SEC CIK 1236927 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| MDGL | MADRIGAL PHARMACEUTICALS, INC. | Dir | 187.4K | — | $126.26M | 22 | 2023-01-16 | 2026-01-09 |
Most active insiders at MDGL, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | FRIEDMAN PAUL A | Dir | — | $26.66M |
| 2 | Taub Rebecca | Dir | — | $21.68M |
| 3 | Sibold William John | Pres, CEO, Dir | — | $10.48M |
| 4 | BATE KENNETH | Dir | — | $8.03M |
| 5 | Levy Richard S | Dir | — | $7.36M |
| 6 | Dier Mardi | EVP, CFO | — | $3.77M |
| 7 | Huntsman Carole | Chief Commercial Off | — | $1.71M |
| 8 | Soergel David | Chief Medical Off | — | $952.0K |
| 9 | Kelley Shannon T | GC | — | $841.6K |
| 10 | Thakkar Rita | CAO | — | — |
Transactions 22
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-01-13 | 2026-01-09 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | FRIEDMAN PAUL A | Dir | M - OptEx | $15.80 | +280 | 187.4K | +0.1% | +$4,424 |
| D | 2026-01-13 | 2026-01-09 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | FRIEDMAN PAUL A | Dir | S - Sale+OE | $551.24 | -280 | 187.2K | -0.1% | -$154.3K |
| DM | 2026-01-13 | 2026-01-09 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | FRIEDMAN PAUL A | Dir | S - Sale+OE | $522.39 | -24.5K | 200.3K | -11% | -$12.81M |
| D | 2026-01-13 | 2026-01-09 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | FRIEDMAN PAUL A | Dir | M - OptEx | $15.80 | +24.5K | 211.7K | +13% | +$387.4K |
| D | 2025-12-12 | 2025-12-10 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | FRIEDMAN PAUL A | Dir | M - OptEx | $15.80 | +24.8K | 212.0K | +13% | +$391.8K |
| DM | 2025-12-12 | 2025-12-10 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | FRIEDMAN PAUL A | Dir | S - Sale+OE | $552.18 | -24.8K | 198.9K | -11% | -$13.69M |
| DM | 2025-08-13 | 2025-08-11+ | MDGL | MADRIGAL PHARMACEUTICALS, INC. | FRIEDMAN PAUL A | Dir | M - OptEx | $9.45 | +46.8K | 230.8K | +25% | +$442.3K |
| DM | 2025-08-13 | 2025-08-11+ | MDGL | MADRIGAL PHARMACEUTICALS, INC. | FRIEDMAN PAUL A | Dir | S - Sale+OE | $355.31 | -46.8K | 222.9K | -17% | -$16.63M |
| D | 2025-08-13 | 2025-08-13 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | FRIEDMAN PAUL A | Dir | M - OptEx | $9.45 | +129.2K | 316.3K | +69% | +$1.22M |
| DM | 2025-08-13 | 2025-08-13 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | FRIEDMAN PAUL A | Dir | S - Sale+OE | $370.24 | -129.2K | 187.2K | -41% | -$47.83M |
| D | 2025-07-22 | 2025-07-18 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | FRIEDMAN PAUL A | Dir | S - Sale+OE | $350.03 | -1,400 | 187.2K | -0.7% | -$490.0K |
| D | 2025-07-22 | 2025-07-18 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | FRIEDMAN PAUL A | Dir | M - OptEx | $9.45 | +1,400 | 188.6K | +0.7% | +$13.2K |
| DM | 2025-07-18 | 2025-07-16+ | MDGL | MADRIGAL PHARMACEUTICALS, INC. | FRIEDMAN PAUL A | Dir | M - OptEx | $9.45 | +28.9K | 189.9K | +18% | +$272.9K |
| DM | 2025-07-18 | 2025-07-16+ | MDGL | MADRIGAL PHARMACEUTICALS, INC. | FRIEDMAN PAUL A | Dir | S - Sale+OE | $353.19 | -28.9K | 187.2K | -13% | -$10.20M |
| D | 2025-06-24 | 2025-06-20 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | FRIEDMAN PAUL A | Dir | A - Grant | $0.00 | +715 | 187.2K | +0.4% | $0 |
| D | 2024-06-27 | 2024-06-25 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | FRIEDMAN PAUL A | Dir | A - Grant | $0.00 | +714 | 186.4K | +0.4% | $0 |
| DMT | 2024-04-10 | 2024-04-08 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | FRIEDMAN PAUL A | Dir | S - Sale+OE | $246.19 | -26.3K | 210.6K | -11% | -$6.47M |
| DT | 2024-04-10 | 2024-04-08 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | FRIEDMAN PAUL A | Dir | M - OptEx | $9.45 | +26.3K | 212.0K | +14% | +$248.3K |
| DM | 2024-04-05 | 2024-04-03+ | MDGL | MADRIGAL PHARMACEUTICALS, INC. | FRIEDMAN PAUL A | Dir | S - Sale+OE | $243.93 | -73.7K | 188.2K | -28% | -$17.98M |
| DM | 2024-04-05 | 2024-04-03+ | MDGL | MADRIGAL PHARMACEUTICALS, INC. | FRIEDMAN PAUL A | Dir | M - OptEx | $9.45 | +73.7K | 213.3K | +53% | +$696.7K |
| 2024-01-18 | 2023-01-16 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | FRIEDMAN PAUL A | Dir | F - Tax | $243.92 | -2,254 | 20.0K | -10% | -$549.8K | |
| 2023-01-18 | 2023-01-16 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | FRIEDMAN PAUL A | CEO, Dir | A - Grant | $0.00 | +26.7K | 26.7K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations